Effect of sex in systemic psoriasis therapy: Differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be pre-scribed biologics. There were no differences between men and women in effectiveness of therapy, measur-ed in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios) and from pharmaceutical companies (Abbott/Abbvie, Pfizer, MSD, Novartis, Lilly, Janssen and Almirall)

Competitividad y Sistemas de Innovación

Un sistema regional de innovación debe servir para analizar la adaptación de los territorios a las nuevas situaciones tecnológicas e industriales y tiene que ser un instrumento para planificar, dinamizar y hacer competitivos los territorios mediante la interacción, movilización y regulación de agentes, recursos, e infraestructuras. Por otra parte, hay que distinguir entre los inputs o medidas políticas que llevan acabo los agentes y administraciones y los ouputs del sistema que son objetivos a alcanzar. Así, un sistema de innovación competitivo es aquel que muestra habilidades para conseguir unos éxitos que garanticen una mejora del nivel de vida de la sociedad

Direct evidence of megamammalcarnivore interaction decoded from bone marks in historical fossil collections from the pampean region

Pleistocene South American megafauna has traditionally attracted the interest of scientists and the popular media alike. However, ecological interactions between the species that inhabited these ecosystems, such as predator-prey relationships or interspecific competition, are poorly known. To this regard, carnivore marks imprinted on the fossil bones of megamammal remains are very useful for deciphering biological activity and, hence, potential interspecific relationships among taxa. In this article, we study historical fossil collections housed in different European and Argentinean museums that were excavated during the 19th and early 20th centuries in the Pampean region, Argentina, in order to detect carnivore marks on bones of megamammals and provide crucial information on the ecological relationships between South American taxa during the Pleistocene. Our results indicate that the long bones of megafauna from the Pampean region (e.g., the Mylodontidae and Toxodontidae families) exhibit carnivore marks. Furthermore, long bones of medium-sized species and indeterminate bones also present punctures, pits, scores and fractures. Members of the large-carnivore guild, such as ursids, canids and even felids, are recognised as the main agents that inflicted the marks. We hypothesize that the analysed carnivore marks represent the last stages of megaherbivore carcass exploitation, suggesting full consumption of these animals by the same or multiple taxa in a hunting and/or scavenging scenario. Moreover, our observations provide novel insights that help further our understanding of the palaeoecological relationships of these unique communities of megamammals.Fil: Chichkoyan, Karina Vanesa. Universitat Rovira i Virgili. Institut Català  de Paleoecologia Humana i Evolució Social; EspañaFil: Figueirido, Borja. Universidad de Málaga; EspañaFil: Belinchón, Margarita. Museo de Ciencias Naturales de Valencia; EspañaFil: Lanata, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte. Instituto de Investigaciones en Diversidad Cultural y Procesos de Cambio. Universidad Nacional de Río Negro. Instituto de Investigaciones en Diversidad Cultural y Procesos de Cambio; ArgentinaFil: Moigne, Anne Marie. Musée de l’Homme; FranciaFil: Martinez Navarro, Bienvenido. Universitat Rovira i Virgili. Institut Català  de Paleoecologia Humana i Evolució Social; España. Institució Catalana de Recerca i Estudis Avancats; Españ

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

Background Limited information is available regarding the risk of incident liver disease in patients with psoriasis receiving systemic therapies. Objectives To describe the liver safety findings of conventional and modern systemic therapies for moderate-to-severe psoriasis, and to compare the relative incidence rates of hepatic adverse events (AEs) for each drug. Methods All the patients on the BIOBADADERM registry were included. Crude and adjusted incidence rate ratios (cIRR and aIRR, respectively) of hepatic AEs, using anti-TNF drugs as reference, were determined. Outcomes of interest were hypertransaminasemia, nonalcoholic fatty liver disease (NADFLD) and a group of other, less represented, hepatic AEs. Results Our study included 3,171 patients exposed to systemic drugs (6279 treatment cycles). Incident hypertransaminasemia was the most frequent hepatic AE (incidence rate of 21 per 1000 patients-years [CI 95% 18–23]), followed by NAFLD (8 cases per 1000 patients-years [95% CI 6–10]). Methotrexate (aIRR 3.06 [2.31–4.4]; p = 0.000) and cyclosporine (aIRR 2.37 [1.05–5.35]; p = .0378) were associated with an increased risk for hypertransaminasemia when compared to anti-TNF-α agents. No differences were observed between different groups of biologics. Conventional therapies were not associated with new incident NAFLD. Conclusions Comparative information of the incidence of hepatic AEs could facilitate drug selection in moderate-to-severe psoriasis

Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.

The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness